Jasper Therapeutics, Inc. · NASDAQ:JSPR
Jasper Therapeutics — ASH Annual Meeting 2023
16 slides from Jasper Therapeutics's conference presentation, Dec 10, 2023
Slide 1: Final Results from Phase 1 Study of Briquilimab in Older Adults with AML and MDS
ASH Annual Meeting – December 10, 2023 Final Results from Phase 1 Study of Briquilimab, an Anti-CD117 Monoclonal Antibody, in Combination with Low Dose Irradiation and Fludarabine Conditioning, Shows Durable Remissions in Older Adults with Acute Myeloid Leukemia in Complete Remission and Myelodyspla
Slide 2: Conflict of Interest
Conflict of Interest Gandhi – None Muffly - Advisory Boards: Pfizer, Amgen, Jazz, Medexus, CTI Biopharma, Kite; Research Funding: Astellas, Jasper, Adaptive, Kite, BMS; Consulting: Astellas Lee - Advisory Boards: Kadmon, Kite, Jazz; Research Funding: Incyte; Consulting: Fresenius Scott- Advisory Boa
Slide 3: Allogeneic HCT rates have significantly increased, especially in over 65 years old, in the U.S.
Allogeneic HCT rates have significantly increased, especially in over 65 years old, in the U.S. <18 Years 18-39 Years 40-64 Years 65+ Years N 3723 3928 4201 4612 4890 5121 5522 5785 6320 6451 6608 6665 6929 7117 7345 7043 7163 100% 4 5 6 8 10 10 12 14 16 19 20 22 22 25 26 28 29 80% Transplants, % 55
Slide 4: Briquilimab Inhibits CD117 Signaling Leading to Transient Clearance of HSCs
Briquilimab Inhibits CD117 (c-Kit; Stem Cell Factor Receptor) Signaling Leading to Transient Clearance of Hematopoietic Stem Cells (HSCs) from Their Bone Marrow Niche Briquilimab Blocks SCF Empty Bone Donor HSC Home Binding to CD117 Marrow Niche to Marrow Niche Stem Cell Factor (SCF) Briquilimab Str
Slide 5: Blockade of CD117 is Synergistic with Low Dose Radiation to Enhance Clearance of HSCs
Blockade of CD117 is Synergistic with Low Dose Radiation to Enhance Clearance of HSCs from the Niche and Enable HSC Engraftment in Immunocompetent Mouse Model Donor HSC Engraftment Anti-CD117 + Radiation only Low Dose Radiation Chhabra et al. Sci Transl Med 2016; Pang et al. ASH 2019 Briquilimab is
Slide 6: Study Design: Single-arm, Open Label, in MDS/AML Patients Not Eligible for Myeloablative Conditioning
Study Design: Single-arm, Open Label, in MDS/AML Patients Not Eligible for Myeloablative Conditioning Regimens Assessments: Primary endpoints: • Safety and tolerability of briquilimab/TBI/Flu • Briquilimab pharmacokinetics Key inclusion criteria: Experimental arm: Secondary endpoints: • MDS or AML B
Slide 7: Treatment Schema: Outpatient Conditioning Regimen
Treatment Schema: Outpatient Conditioning Regimen TBI Bone marrow Fludarabine (Flu) 200- Mobilized Briquilimab aspiration/biopsy 30 mg/m2/day 300 cGy PB HCT Transplant -10 to -7 -6 -5 -4 -3 -2 -1 0 Day (TD) -14 • Real-time PK measurements and modeling were used to determine Flu start date • TBI incr
Slide 8: MDS & AML Patient Characteristics
MDS & AML Patient Characteristics Characteristic All AML in CR MDS AML not in CR (N = 32) (N=13) (N = 16) (N = 3) Median age (range) - year 70 (62-79) 70 (62-79) 70 (63-77) 66 (66-69) Sex – no. (%) Male 20 (62.5%) 8 (61.5%) 11 (68.8%) 1 (33.3%) Female 12 (37.5%) 5 (38.5%) 5 (31.3%) 2 (66.7%) Prior A
Slide 9: 0.6 mg/kg IV Briquilimab PK: Consistent and Predictable Clearance
0.6 mg/kg IV Briquilimab PK: Consistent and Predictable Clearance Concentration of JSP191 in 30000 10000 Serum (ng/mL) 3000 1000 300 100 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Time (days) Briquilimab is an investigational agent and not approved for any indication. 9
Slide 10: Safety and Tolerability
Safety and Tolerability • No significant briquilimab infusion reactions • No briquilimab-related SAEs • No primary graft failure (one case of secondary graft failure) TEAE within 30 Days Post-transplant by Severity Grade Total (N=32) Grade 1-2 11 (34.4%) Grade 3 17 (53.1%) Grade 4 4 (12.5%)* *Grade
Slide 11: Briquilimab + 200-300 cGy TBI Resulted in Neutropenia Followed by Neutrophil Engraftment by TD+26
Briquilimab + 200-300 cGy TBI in All Patients Resulted in Neutropenia Followed by Neutrophil Engraftment by TD+26 Briquilimab is an investigational agent and not approved for any indication. 11
Slide 12: Median donor myeloid chimerism of 99% and median total chimerism of 95% at TD+90
Median donor myeloid chimerism of 99% (range 96-100%) and median total chimerism of 95% (range 81-100%) at TD+90 Total Chimerism Myeloid Chimerism T Cell Chimerism 100 100 100 % Donor derived in 80 % Donor derived in 80 % Donor derived in 80 CD3+ cells CD15+ cells total PBMC 60 60 60 40 40 40 20 20
Slide 13: Final 1-year Efficacy Outcomes
Final 1-year Efficacy Outcomes At 1-year AML in CR (n=13) MDS (n=16) • Measurable residual disease Relapse/Progression 3 (23.1%) 5 (31.3%) (MRD) was tested using cytogenetics, flow cytometry and NRM 1 (7.7%) 1 (6.3%) next gen sequencing prior to and MRD Negative 8 (61.5%) 6 (37.5%) after HCT Relapse
Slide 14: Final 1-year Efficacy Outcomes: Overall and Relapse-Free Survival
Final 1-year Efficacy Outcomes Overall Survival Relapse-Free Survival 1.0 1.0 ○ Censored 0.8 0.8 Survival Probability Survival Probability 0.6 0.6 ≈ ≈ 0.4 0.4 0.2 0.2 0.0 0.0 0 28 56 90 120 150 180 210 240 270 300 330 360 ≈ 0 28 56 90 120 150 180 210 240 270 300 330 360 ≈ AML in CR MDS AML R/R AML i
Slide 15: Summary of Phase 1 Trial Results
Summary of Phase 1 Trial Results • Briquilimab at a dose of 0.6 mg/kg has predictable clearance and allows donor cell infusion at 9-14 days after briquilimab • All patients engrafted with neutrophil recovery before Transplant Day +26 • Briquilimab/Flu/TBI is a novel conditioning regimen that appears
Slide 16: Acknowledgements
Acknowledgements • Jasper Therapeutics and the Investigators would like to thank the patients and families for participating in this clinical trial (NCT#04429191). • We would also like to thank the participating clinical sites, clinical staff, and collaborators Briquilimab is an investigational agen